Inhibitor development and mortality in non‐severe hemophilia A

Autor: Eckhardt, C.L., Loomans, J.I., van Velzen, A.S., Peters, M., Mauser‐Bunschoten, E.P., Schwaab, R., Mazzucconi, M.G., Tagliaferri, A., Siegmund, B., Reitter‐Pfoertner, S.E., van der Bom, J.G., Fijnvandraat, K. ^*, Kamphuisen, P.W., Peerlinck, K., Oldenburg, J., Santagostino, E., Astermark, J., Eckhardt, C.L, van Velzen, A.S, Streefkerk, N., Loomans, J.L., van Eijkelenburg, A., Jansen, A.J., Kruijt, C.C., van Tienoven, B., van Baar, A.C.G., Corten, I.W., Meijer, K., Nijziel, M.R., Dors, N., Hamulyak, K., Beckers, E., Brons, P.P., Laros‐van Gorkom, B.A.P., van Heerde, W.L., Leebeek, F., Kruip, M., Cnossen, M.H., Mauser‐Bunschoten, E., Fischer, K., Smiers, F.J., Hermans, C., Klamroth, R., Escuriola‐Ettingshausen, C., Königs, C., Petrini, P., Holmström, M., Mäkipernaa, A., Male, C., Pabinger, I., Keenan, R.D., Liesner, R., Khair, K., Yee, T.T., Hart, D.P., Rangarajan, S., Mitchell, M., Thompson, G., Haya, S., Moret, A., Cid, A.R., Jimenez‐Yuste, V., Mancuso, M.E., Mazzuconni, M.G., Santoro, C., Morfini, M., Castaman, G., Schinco, P., Rivolta, G.F., Platokouki, H., McRae, S.

Publikováno v: In Journal of Thrombosis and Haemostasis July 2015 13(7):1217-1225

The incidence and magnitude of fibrinolytic activation in trauma patients

Autor: RAZA, I. ^*, DAVENPORT, R., ROURKE, C., PLATTON, S., MANSON, J., SPOORS, C., KHAN, S., De'ATH, H.D., ALLARD, S., HART, D.P., PASI, K.J., HUNT, B.J., STANWORTH, S., MacCALLUM, P.K., BROHI, K.

Publikováno v: In Journal of Thrombosis and Haemostasis February 2013 11(2):307-314

Delivery of AAV‐based gene therapy through haemophilia centres—A need for re‐evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC

Autor: Miesbach, W., Chowdary, P., Coppens, M., Hart, D.P., Jimenez‐Yuste, V., Klamroth, R., Makris, M., Noone, D., Peyvandi, F.

Introduction\ud \ud Adeno-associated virus (AAV)-based gene therapy for haemophilia presents a challenge to the existing structure of haemophilia centres and requires a rethink of current collaboration and information exchange with the aim of ensurin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::30c07312ca2cd122d229bf7961f09ea1
https://eprints.whiterose.ac.uk/178801/1/hae.14420.pdf

The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors

Autor: Velzen, A.S. van, Eckhardt, C.L., Streefkerk, N., Peters, M., Hart, D.P., Hamulyak, K., Klamroth, R., Meijer, K., Nijziel, M.R., Schinco, P., Yee, T.T, Bom, J.G. Van Der, Fijnvandraat, K., Brons, P.P., Laros-van Gorkom, B.A.P.

Publikováno v: Thrombosis and haemostasis, 115(3), 543-550. Schattauer GmbH
THROMBOSIS AND HAEMOSTASIS
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Thrombosis and Haemostasis, 115, 3, pp. 543-50
Thrombosis and Haemostasis, 115(3), 543-550
Thrombosis and Haemostasis
Thrombosis and Haemostasis, 115(3), 543-550. Georg Thieme Verlag
Thrombosis and Haemostasis, 115, 543-50
Thrombosis and Haemostasis, 115(3), 543-550. GEORG THIEME VERLAG KG

SummaryThe development of an inhibitory antibody in non-severe haemophilia A patients may aggravate the bleeding phenotype considerably. Effective treatment of bleeding episodes may be challenging, with ensuing severe complications. At present, evide

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8035b23c782f6f7751ce0c65f5771bfd
https://doi.org/10.1160/th15-03-0212

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.